

AMENDMENT

I. Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-75. (Cancelled)

76. (Currently amended) An ApoA-I agonist compound comprising:

(i) an 18 to 22-residue peptide or peptide analogue which forms an amphipathic α -helix in the presence of lipids and which comprises formula (I):

Z₁-X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆-X₁₇-X₁₈-Z₂

or a pharmaceutically acceptable salt thereof, wherein

X₁ is Pro (P), Ala (A), Gly (G), Asn (N), Gln (Q) or D-pro (p);

X₂ is an aliphatic residue;

X₃ is Leu (L);

X₄ is an acidic residue;

X₅ is Leu (L) or Phe (F);

X₆ is Leu (L) or Phe (F);

X₇ is a basic residue;

X₈ is an acidic residue;

X₉ is Leu (L) or Trp (W);

X₁₀ is Leu (L) or Trp (W);

X₁₁ is an acidic residue or Asn (N);

X₁₂ is an acidic residue;

X₁₃ is Leu (L), Trp (W) or Phe (F);

X₁₄ is a basic residue or Leu (L);

X₁₅ is Gln (Q) or Asn (N);

X₁₆ is a basic residue;

X₁₇ is Leu (L);

X₁₈ is a basic residue;

Okay to
enter
JRL
11-14-2003